New Risk • Jun 01
New major risk - Revenue and earnings growth Earnings have declined by 3.3% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 3.3% per year over the past 5 years. High level of non-cash earnings (21% accrual ratio). Market cap is less than US$10m (₹233.4m market cap, or US$2.46m). Minor Risk Paying a dividend despite having no free cash flows. Reported Earnings • Jun 01
Full year 2026 earnings released: EPS: ₹10.39 (vs ₹11.43 in FY 2025) Full year 2026 results: EPS: ₹10.39 (down from ₹11.43 in FY 2025). Revenue: ₹573.6m (up 3.4% from FY 2025). Net income: ₹42.5m (down 9.1% from FY 2025). Profit margin: 7.4% (down from 8.4% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has fallen by 39% per year, which means it is performing significantly worse than earnings. 공시 • May 23
Prolife Industries Limited to Report Second Half, 2026 Results on May 29, 2026 Prolife Industries Limited announced that they will report second half, 2026 results on May 29, 2026 Valuation Update With 7 Day Price Move • Apr 22
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹69.35, the stock trades at a trailing P/E ratio of 11.8x. Average trailing P/E is 22x in the Chemicals industry in India. Total loss to shareholders of 65% over the past three years. Valuation Update With 7 Day Price Move • Feb 27
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₹60.15, the stock trades at a trailing P/E ratio of 10.2x. Average trailing P/E is 22x in the Chemicals industry in India. Total loss to shareholders of 71% over the past three years. Valuation Update With 7 Day Price Move • Feb 11
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹70.10, the stock trades at a trailing P/E ratio of 11.9x. Average trailing P/E is 23x in the Chemicals industry in India. Total loss to shareholders of 72% over the past year. New Risk • Jan 17
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.4% average weekly change). Market cap is less than US$10m (₹274.3m market cap, or US$3.02m). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (4.2% net profit margin). Valuation Update With 7 Day Price Move • Jan 05
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹67.00, the stock trades at a trailing P/E ratio of 11.4x. Average trailing P/E is 24x in the Chemicals industry in India. Total loss to shareholders of 70% over the past three years. New Risk • Dec 01
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$10m (₹334.5m market cap, or US$3.74m). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (4.2% net profit margin). Valuation Update With 7 Day Price Move • Nov 19
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹80.00, the stock trades at a trailing P/E ratio of 7x. Average trailing P/E is 25x in the Chemicals industry in India. Total loss to shareholders of 52% over the past three years. 공시 • Nov 13
Prolife Industries Limited to Report First Half, 2026 Results on Nov 14, 2025 Prolife Industries Limited announced that they will report first half, 2026 results on Nov 14, 2025 Board Change • Nov 11
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 1 highly experienced director. Executive Director Siddharth Raghuvanshi was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Valuation Update With 7 Day Price Move • Sep 10
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₹107, the stock trades at a trailing P/E ratio of 9.3x. Average trailing P/E is 27x in the Chemicals industry in India. Total loss to shareholders of 30% over the past three years. Upcoming Dividend • Sep 09
Upcoming dividend of ₹0.30 per share Eligible shareholders must have bought the stock before 16 September 2025. Payment date: 23 October 2025. Payout ratio is a comfortable 2.6% but the company is not cash flow positive. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.3%). Lower than average of industry peers (0.7%). Declared Dividend • Aug 25
Dividend reduced to ₹0.30 Dividend of ₹0.30 is 40% lower than last year. Ex-date: 16th September 2025 Payment date: 23rd October 2025 Dividend yield will be 0.2%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (3% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 12% per year over the past 8 years and payments have been stable during that time. Earnings per share has grown by 3.0% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. 공시 • Aug 23
Prolife Industries Limited announces Annual dividend, payable on October 23, 2025 Prolife Industries Limited announced Annual dividend of INR 0.3000 per share payable on October 23, 2025, ex-date on September 16, 2025 and record date on September 16, 2025. 공시 • Aug 22
Prolife Industries Limited, Annual General Meeting, Sep 23, 2025 Prolife Industries Limited, Annual General Meeting, Sep 23, 2025, at 09:00 Indian Standard Time. Location: 6,8,10,12 hexzone arcade, nr. jayaben modi hospital, valia rd., g.i.d.c., gujarat - 393002., anleshwar India New Risk • Jun 27
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 8.1% Last year net profit margin: 15% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (23% accrual ratio). Market cap is less than US$10m (₹646.9m market cap, or US$7.56m). Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (8.1% net profit margin). New Risk • Jun 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (23% accrual ratio). Market cap is less than US$10m (₹634.6m market cap, or US$7.40m). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.0% average weekly change). Valuation Update With 7 Day Price Move • Jun 04
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹146, the stock trades at a trailing P/E ratio of 7.9x. Average trailing P/E is 27x in the Chemicals industry in India. Total loss to shareholders of 11% over the past three years. New Risk • Jun 02
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (23% accrual ratio). Market cap is less than US$10m (₹678.8m market cap, or US$7.95m). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Paying a dividend despite having no free cash flows. New Risk • May 09
New minor risk - Dividend sustainability The dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 0.3% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (23% accrual ratio). Market cap is less than US$10m (₹704.4m market cap, or US$8.21m). Minor Risk Paying a dividend despite having no free cash flows. New Risk • Mar 10
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹873.3m (US$10.00m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.8% average weekly change). High level of non-cash earnings (23% accrual ratio). Market cap is less than US$10m (₹873.3m market cap, or US$10.00m). Valuation Update With 7 Day Price Move • Jan 14
Investor sentiment deteriorates as stock falls 22% After last week's 22% share price decline to ₹268, the stock trades at a trailing P/E ratio of 14.5x. Average trailing P/E is 29x in the Chemicals industry in India. Total returns to shareholders of 60% over the past three years. Valuation Update With 7 Day Price Move • Dec 30
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₹318, the stock trades at a trailing P/E ratio of 17.2x. Average trailing P/E is 31x in the Chemicals industry in India. Total returns to shareholders of 119% over the past three years. Valuation Update With 7 Day Price Move • Nov 28
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹299, the stock trades at a trailing P/E ratio of 16.2x. Average trailing P/E is 32x in the Chemicals industry in India. Total returns to shareholders of 149% over the past three years. New Risk • Nov 16
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 23% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (23% accrual ratio). Minor Risk Market cap is less than US$100m (₹1.20b market cap, or US$14.2m). Valuation Update With 7 Day Price Move • Nov 08
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹296, the stock trades at a trailing P/E ratio of 13.9x. Average trailing P/E is 35x in the Chemicals industry in India. Total returns to shareholders of 143% over the past three years. Valuation Update With 7 Day Price Move • Oct 10
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹255, the stock trades at a trailing P/E ratio of 11.9x. Average trailing P/E is 35x in the Chemicals industry in India. Total returns to shareholders of 147% over the past three years. 공시 • Sep 24
Prolife Industries Limited Approves Final Dividend for the Financial Year 2023-24 Prolife Industries Limited at its AGM held on September 23, 2024 approved final dividend of INR 0.50 per shares on Equity shares of face value INR 10/- for the financial year 2023-24. Upcoming Dividend • Sep 11
Upcoming dividend of ₹0.50 per share Eligible shareholders must have bought the stock before 16 September 2024. Payment date: 23 October 2024. Payout ratio is a comfortable 2.3% and this is well supported by cash flows. Trailing yield: 0.2%. Lower than top quartile of Indian dividend payers (1.0%). Lower than average of industry peers (0.6%). Valuation Update With 7 Day Price Move • Sep 04
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹249, the stock trades at a trailing P/E ratio of 11.6x. Average trailing P/E is 36x in the Chemicals industry in India. Total returns to shareholders of 177% over the past three years. New Risk • Aug 29
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹838.1m (US$9.99m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company. Declared Dividend • Aug 28
Dividend of ₹0.50 announced Shareholders will receive a dividend of ₹0.50. Ex-date: 16th September 2024 Payment date: 23rd October 2024 Dividend yield will be 0.2%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (1% earnings payout ratio) and cash flows (0.7587% cash payout ratio). The dividend has increased by an average of 6.0% per year over the past 7 years and payments have been stable during that time. Earnings per share has grown by 34% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. 공시 • Aug 26
Prolife Industries Limited, Annual General Meeting, Sep 23, 2024 Prolife Industries Limited, Annual General Meeting, Sep 23, 2024, at 09:00 Indian Standard Time. Location: 6,8,10,12 hexzone arcade, nr. jayaben modi hospital, valia rd., g.i.d.c., anleshwar- 393002., India New Risk • Aug 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₹1.03b market cap, or US$12.3m). Valuation Update With 7 Day Price Move • Aug 01
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹241, the stock trades at a trailing P/E ratio of 11.3x. Average trailing P/E is 35x in the Chemicals industry in India. Total returns to shareholders of 136% over the past three years. Reported Earnings • Jun 04
Full year 2024 earnings released: EPS: ₹21.40 (vs ₹16.89 in FY 2023) Full year 2024 results: EPS: ₹21.40 (up from ₹16.89 in FY 2023). Revenue: ₹584.2m (down 25% from FY 2023). Net income: ₹87.6m (up 27% from FY 2023). Profit margin: 15% (up from 8.8% in FY 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 21% per year whereas the company’s share price has increased by 26% per year. New Risk • May 21
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₹851.6m market cap, or US$10.2m). Valuation Update With 7 Day Price Move • Mar 15
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₹220, the stock trades at a trailing P/E ratio of 10.7x. Average trailing P/E is 28x in the Chemicals industry in India. Total returns to shareholders of 315% over the past three years. Valuation Update With 7 Day Price Move • Jan 12
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹286, the stock trades at a trailing P/E ratio of 13.9x. Average trailing P/E is 31x in the Chemicals industry in India. Total returns to shareholders of 365% over the past three years. Board Change • Dec 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 1 highly experienced director. Executive Director Siddharth Raghuvanshi was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Nov 10
Investor sentiment improves as stock rises 28% After last week's 28% share price gain to ₹255, the stock trades at a trailing P/E ratio of 12.4x. Average trailing P/E is 28x in the Chemicals industry in India. Total returns to shareholders of 552% over the past three years. New Risk • Oct 25
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹812.7m (US$9.77m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (26% accrual ratio). Market cap is less than US$10m (₹812.7m market cap, or US$9.77m). Upcoming Dividend • Sep 06
Upcoming dividend of ₹0.30 per share at 0.1% yield Eligible shareholders must have bought the stock before 13 September 2023. Payment date: 20 October 2023. Payout ratio is a comfortable 1.8% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of Indian dividend payers (1.3%). Lower than average of industry peers (0.8%). 공시 • Aug 25
Prolife Industries Limited, Annual General Meeting, Sep 20, 2023 Prolife Industries Limited, Annual General Meeting, Sep 20, 2023, at 09:00 Indian Standard Time. Location: 6,8,10,12 HEXZONE ARCADE NR. JAYABEN MODI HOSPITAL, VALIA ROAD, G.I.D.C. ANKLESHWAR- 393002 Ankleshwar India Agenda: To consider and approve the Audited Financial Statements of the Company for the financial year ended March 31, 2023, together with the Reports of the Board of Directors and the Auditors thereon; to consider and approve the appointment of a Director in place of Mrs. Anureet Kaur M Jolly who retires by rotation in terms of section 152(6) of the Companies Act, 2013 and being eligible to offer herself for re-appointment; and to consider other matters. Valuation Update With 7 Day Price Move • Jul 17
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹245, the stock trades at a trailing P/E ratio of 14.5x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 704% over the past three years. Valuation Update With 7 Day Price Move • Jun 07
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹229, the stock trades at a trailing P/E ratio of 13.6x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 39% over the past year. Reported Earnings • Jun 01
Full year 2023 earnings released: EPS: ₹16.89 (vs ₹10.51 in FY 2022) Full year 2023 results: EPS: ₹16.89 (up from ₹10.51 in FY 2022). Revenue: ₹805.0m (up 10.0% from FY 2022). Net income: ₹69.1m (up 61% from FY 2022). Profit margin: 8.6% (up from 5.9% in FY 2022). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • May 18
Investor sentiment improves as stock rises 28% After last week's 28% share price gain to ₹243, the stock trades at a trailing P/E ratio of 20.4x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 47% over the past year. Valuation Update With 7 Day Price Move • Dec 16
Investor sentiment improved over the past week After last week's 24% share price gain to ₹202, the stock trades at a trailing P/E ratio of 16.9x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 598% over the past three years. Reported Earnings • Nov 16
First half 2023 earnings released: EPS: ₹8.43 (vs ₹7.01 in 1H 2022) First half 2023 results: EPS: ₹8.43 (up from ₹7.01 in 1H 2022). Revenue: ₹438.1m (up 24% from 1H 2022). Net income: ₹34.5m (up 20% from 1H 2022). Profit margin: 7.9% (down from 8.1% in 1H 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 84% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Sep 10
Full year 2022 earnings released: EPS: ₹10.51 (vs ₹13.43 in FY 2021) Full year 2022 results: EPS: ₹10.51 (down from ₹13.43 in FY 2021). Revenue: ₹732.0m (flat on FY 2021). Net income: ₹43.0m (down 22% from FY 2021). Profit margin: 5.9% (down from 7.5% in FY 2021). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 86% per year, which means it is tracking significantly ahead of earnings growth. Board Change • May 31
High number of new directors Executive Director Siddharth Raghuvanshi was the last director to join the board, commencing their role in 2020. Board Change • Apr 27
High number of new directors Executive Director Siddharth Raghuvanshi was the last director to join the board, commencing their role in 2020. Valuation Update With 7 Day Price Move • Feb 08
Investor sentiment deteriorated over the past week After last week's 18% share price decline to ₹156, the stock trades at a trailing P/E ratio of 11.6x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 470% over the past three years. Valuation Update With 7 Day Price Move • Jan 21
Investor sentiment improved over the past week After last week's 18% share price gain to ₹182, the stock trades at a trailing P/E ratio of 13.6x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 503% over the past three years. Valuation Update With 7 Day Price Move • Dec 28
Investor sentiment improved over the past week After last week's 18% share price gain to ₹130, the stock trades at a trailing P/E ratio of 9.7x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 125% over the past year. Valuation Update With 7 Day Price Move • Nov 01
Investor sentiment improved over the past week After last week's 16% share price gain to ₹120, the stock trades at a trailing P/E ratio of 8.9x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 309% over the past three years. Board Change • Nov 01
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Chairman & MD Karan Jolly was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Board Change • Oct 15
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Chairman & MD Karan Jolly was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Upcoming Dividend • Sep 15
Upcoming dividend of ₹0.30 per share Eligible shareholders must have bought the stock before 22 September 2021. Payment date: 29 October 2021. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (0.7%). Executive Departure • Sep 11
Company Secretary & Compliance Officer Darshna Maniyar has left the company On the 3rd of September, Darshna Maniyar's tenure as Company Secretary & Compliance Officer ended after 5.0 years in the role. We don't have any record of a personal shareholding under Darshna's name. Darshna is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 5.08 years. Valuation Update With 7 Day Price Move • Aug 20
Investor sentiment improved over the past week After last week's 15% share price gain to ₹101, the stock trades at a trailing P/E ratio of 7.6x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 266% over the past three years. Valuation Update With 7 Day Price Move • Jul 19
Investor sentiment improved over the past week After last week's 16% share price gain to ₹101, the stock trades at a trailing P/E ratio of 7.6x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 249% over the past three years. Valuation Update With 7 Day Price Move • May 30
Investor sentiment improved over the past week After last week's 28% share price gain to ₹70.65, the stock trades at a trailing P/E ratio of 5.3x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 118% over the past three years. Valuation Update With 7 Day Price Move • May 14
Investor sentiment improved over the past week After last week's 16% share price gain to ₹48.80, the stock trades at a trailing P/E ratio of 3.7x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 65% over the past three years. Valuation Update With 7 Day Price Move • Jan 08
Investor sentiment improved over the past week After last week's 16% share price gain to ₹64.75, the stock is trading at a trailing P/E ratio of 4.9x, up from the previous P/E ratio of 4.2x. This compares to an average P/E of 19x in the Chemicals industry in India. Total returns to shareholders over the past three years are 90%. Valuation Update With 7 Day Price Move • Dec 18
Investor sentiment improved over the past week After last week's 19% share price gain to ₹63.50, the stock is trading at a trailing P/E ratio of 4.8x, up from the previous P/E ratio of 4x. This compares to an average P/E of 18x in the Chemicals industry in India. Total returns to shareholders over the past three years are 91%. Valuation Update With 7 Day Price Move • Dec 02
Market bids up stock over the past week After last week's 16% share price gain to ₹43.35, the stock is trading at a trailing P/E ratio of 3.3x, up from the previous P/E ratio of 2.8x. This compares to an average P/E of 16x in the Chemicals industry in India. Total returns to shareholders over the past three years are 12%. 
